Rhumbline Advisers Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rhumbline Advisers raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 5.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 426,527 shares of the medical equipment provider's stock after acquiring an additional 22,889 shares during the period. Rhumbline Advisers owned approximately 0.22% of Zimmer Biomet worth $48,274,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ZBH. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the 4th quarter worth $25,000. Menard Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $30,000. Accredited Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $36,000. Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $40,000. Institutional investors and hedge funds own 88.89% of the company's stock.

Analysts Set New Price Targets

Several analysts recently commented on ZBH shares. Raymond James reduced their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Morgan Stanley reduced their price objective on shares of Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Robert W. Baird reduced their price objective on shares of Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Barclays reduced their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Monday, February 10th. Finally, Royal Bank of Canada dropped their target price on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Trading Up 0.4%

Shares of NYSE ZBH traded up $0.36 during midday trading on Thursday, reaching $91.82. 1,265,442 shares of the stock were exchanged, compared to its average volume of 1,797,707. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The stock has a 50 day moving average price of $98.78 and a 200-day moving average price of $104.41. The company has a market capitalization of $18.17 billion, a P/E ratio of 20.63, a P/E/G ratio of 1.95 and a beta of 0.78. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same period in the previous year, the firm earned $1.94 earnings per share. Zimmer Biomet's revenue was up 1.1% compared to the same quarter last year. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a yield of 1.05%. Zimmer Biomet's payout ratio is 21.24%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.